Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Real-world evidence: experiences and challenges for decision making in Latin America
Indexado
WoS WOS:001129316100001
Scopus SCOPUS_ID:85180385509
DOI 10.1017/S0266462323002647
Año 2023
Tipo artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



ObjectiveThe Health Technology Assessment (HTA) process aims to optimize health system funding of technologies. In recent years there has been an increase in what is known as Real-World Evidence (RWE) as a complement to clinical trials. The objective of Health Technology Assessment International's Latin American Policy Forum 2022 was to explore the utility of incorporating RWE into HTA and decision-making processes in the region.MethodsThis article is based on a background document, survey, and the deliberative work of the country representatives who participated in the Forum.ResultsThere is a growing interest in the use of Real-World Data / Real-World Evidence in HTA processes in Latin America, although currently there are no specific local guidelines for RWE use by HTA agencies. At present, its use is limited to certain areas such as adding context to HTA reports, the evaluation of adverse events, or cost estimation.Potential future uses of RWE were identified, including the creation of risk-sharing agreements, the assessment of technology performance in routine practice, providing information on outcomes that are not so easily evaluated in clinical trials (e.g., the identification of specific subpopulations or quality of life), and the estimation of input parameters for economic evaluations.ResultsThere is a growing interest in the use of Real-World Data / Real-World Evidence in HTA processes in Latin America, although currently there are no specific local guidelines for RWE use by HTA agencies. At present, its use is limited to certain areas such as adding context to HTA reports, the evaluation of adverse events, or cost estimation.Potential future uses of RWE were identified, including the creation of risk-sharing agreements, the assessment of technology performance in routine practice, providing information on outcomes that are not so easily evaluated in clinical trials (e.g., the identification of specific subpopulations or quality of life), and the estimation of input parameters for economic evaluations.ConclusionsThe participants agreed that there are several areas presenting significant potential to expand the application of RWD/RWE and that the development of normative frameworks for its use could be helpful.

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Public, Environmental & Occupational Health
Health Care Sciences & Services
Medical Informatics
Scopus
Sin Disciplinas
SciELO
Sin Disciplinas

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 Garcia Marti, Sebastian - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) - Argentina
Institute for Clinical Effectiveness and Health Policy, Ciudad Autonoma de Buenos Aires - Argentina
2 Pichon-Riviere, Andres Hombre Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) - Argentina
Institute for Clinical Effectiveness and Health Policy, Ciudad Autonoma de Buenos Aires - Argentina
3 Augustovski, Federico - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET) - Argentina
Institute for Clinical Effectiveness and Health Policy, Ciudad Autonoma de Buenos Aires - Argentina
4 ESPINOZA-SEPULVEDA, MANUEL ANTONIO Hombre Pontificia Universidad Católica de Chile - Chile

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
Health Technology Assessment International (HTAi)
Institute for Clinical Effectiveness and Health Policy (IECS) from HTAi
Institute for Clinical Effectiveness and Health Policy
Health Technology Assessment international

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
The organization of, and participation at, the Forum was funded by Health Technology Assessment International (HTAi). The preparation of this manuscript was completed by the Institute for Clinical Effectiveness and Health Policy (IECS) with funding from HTAi.
The organization of, and participation at, the Forum was funded by Health Technology Assessment International (HTAi). The preparation of this manuscript was completed by the Institute for Clinical Effectiveness and Health Policy (IECS) with funding from HTAi.

Muestra la fuente de financiamiento declarada en la publicación.